The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
about
Role of Akt signaling in resistance to DNA-targeted therapyABC- and SLC-Transporters in Murine and Bovine Mammary Epithelium--Effects of ProchlorazPolymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia.Bile formation and secretion.Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.The obligatory intestinal folate transporter PCFT (SLC46A1) is regulated by nuclear respiratory factor 1.Augmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphateThe human proton-coupled folate transporter: Biology and therapeutic applications to cancer.Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma.Systemic methotrexate therapy for psoriasis: past, present and future.The intestinal absorption of folates.Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemiaThe reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasisMembrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.An Introspective Update on the Influence of miRNAs in Breast Carcinoma and Neuroblastoma ChemoresistanceDose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.Functional regulation of P-glycoprotein at the blood-brain barrier in proton-coupled folate transporter (PCFT) mutant mice.Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance.Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitorsThe antifolatesPolymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment.Emerging new paradigms for ABCG transporters.ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer.Efflux pump inhibitors: a strategy to combat P-glycoprotein and the NorA multidrug resistance pump.Thymidylate synthase inhibitors for non-small cell lung cancer.Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition.Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism.Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug-resistant cancer by a newly synthesized Schiff base copper chelate.Impaired NFKBIE gene function decreases cellular uptake of methotrexate by down-regulating SLC19A1 expression in a human rheumatoid arthritis cell line.Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance.Antiepileptic drugs alter the expression of placental carriers: An in vitro study in a human placental cell line.Methotrexate-grafted-oligochitosan micelles as drug carriers: synthesis and biological evaluations.Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance.Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers.
P2860
Q28066950-DDB2C980-5EDA-4185-89B0-4C7B691CEDA1Q28551062-480C4C3A-3489-4E02-93EB-D3C02017643DQ33395469-993FEA72-0A2E-4EDD-AB7A-61DBD85F29E7Q33881922-73B5AED6-8AE5-40A6-A75B-4FC5435D98EFQ34101040-4CB2B45B-8CD1-413B-8B50-EF71DBAF0935Q34132226-114E9805-F64E-40C7-A08C-C237D8D81041Q34272508-932CFBC8-60D7-4227-846F-3BDFC240B3F1Q34297931-CDF12049-BAFD-41E0-B0EB-3DD43308CE3AQ34355646-7BFA8CEF-4A48-4CCA-8D04-F18289C88458Q34356265-E8C07B04-CFD2-4DE7-9CB4-3F1CDC73F2F6Q34403349-B21A58C3-B619-4DA0-AF7C-ACCB4D94C7C7Q34619287-6AC4A597-03E2-4DCC-929C-13C493610660Q34656357-C3953FDA-B5FD-428F-B1AF-10558ADA8CE6Q34658009-A46E3137-7BFC-4B92-8BC4-9BBC183891DEQ34753903-9F1DE7C8-F872-497E-AE2A-112E97245DB5Q35415573-74E74E68-40FE-464A-BA4D-30410A2711DEQ35684384-B7FDE4D5-129D-4DFC-8DDE-AE4C74600D54Q36615181-B2DF85D2-085E-428B-A3F4-67769AAAF40CQ36715943-00D15DAC-D75A-4368-96C3-F2B39750587AQ36976346-4DDF069F-BB6A-4EDA-9A7C-92923B4D8B6DQ37078093-2025ABC1-8200-4490-A4A4-1974957BB9F6Q37183495-B05B019D-5776-4BAB-850D-077FB4C6AC6AQ37204143-5446E37F-9C77-42B6-B797-EA8BA19335FAQ37233815-6668394F-E585-4C5E-839F-AA270EAF5E54Q37595188-BC4D789D-B121-4E17-B46A-38FFBD01EA1FQ37725822-419FC919-43D8-4196-8F81-E0CD6F3C883BQ37929783-90079E90-4ABB-41B8-BC31-461E60323448Q38055067-50786182-2285-4AA2-AC20-FB5257FA859EQ38207943-BFC2F71C-0E15-46C9-839B-2D4484578499Q38266172-3A6A5AE1-7526-434A-B7E4-5E3717AD019CQ38402177-FE56E319-B13B-41A0-93AE-5D7CD0A79663Q38806350-967DE69E-D492-4BFD-9FD5-68F4EDCE8A95Q38818138-C2D51CB9-B909-4395-A07E-C72C9E7DB64FQ38821227-4229007A-F103-4050-8B9D-4757DAF05FF2Q38868683-4BD16B82-0831-48D4-94E0-2542263C66CFQ38910253-F70886D3-AD95-444D-9AB5-620B36CD371DQ38924917-6C81712D-99EF-4DFA-90B3-AA21452D2983Q39748993-D0984DB4-1514-474E-AD51-49A0B1B42CB5Q39874489-B72751E0-1F37-4BF9-A5CD-977E995BC254Q40129655-C4CDE82F-C170-4D0D-B48F-6FB5A1E82630
P2860
The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The role of multidrug resistan ...... stance and folate homeostasis.
@ast
The role of multidrug resistan ...... stance and folate homeostasis.
@en
type
label
The role of multidrug resistan ...... stance and folate homeostasis.
@ast
The role of multidrug resistan ...... stance and folate homeostasis.
@en
prefLabel
The role of multidrug resistan ...... stance and folate homeostasis.
@ast
The role of multidrug resistan ...... stance and folate homeostasis.
@en
P1476
The role of multidrug resistan ...... istance and folate homeostasis
@en
P2093
Yehuda G Assaraf
P304
P356
10.1016/J.DRUP.2006.09.001
P577
2006-08-01T00:00:00Z